Researchers at the University of Texas Health Science Center at San Antonio are working on a new pill that could be a game-changer in weight loss. The pill, called CPACC, has shown promising results in mice and could potentially prevent weight gain while promoting weight loss, all without the need for extreme dieting.
Dr. Madesh Muniswamy, a professor of medicine leading the research, stated that the team is making significant progress and clinical trials could begin in as little as two months. However, approval from the Institutional Review Board is still needed before proceeding. The team plans to test different methods of administering the drug, including oral, intravenous, and intraperitoneal, but they aim to minimize the need for daily injections.
The weight loss drug has already proven successful in mice on a high-sugar and high-fat diet, suggesting that it could have similar effects on humans struggling to lose weight. While the drug is most effective when combined with a balanced diet and physical activity, it has the potential to help individuals who have difficulty maintaining healthy eating habits or cannot exercise.
CPACC works by inhibiting the cells’ uptake of magnesium, which plays a crucial role in cellular energy production and usage. By mimicking the deletion of the gene that controls magnesium flow in cells, the drug helps the body process fats and sugars more efficiently, leading to weight loss.
The development of CPACC comes amidst a weight loss drug craze, with injectables like Ozempic and Wegovy gaining popularity. However, CPACC shows potential to rival these drugs once it hits the market. Ozempic and Wegovy target insulin and metabolism, while CPACC focuses on inhibiting magnesium uptake.
The researchers believe that CPACC could reduce the risk of cardiometabolic diseases, such as heart attack and stroke, and lower the incidence of liver cancer associated with fatty liver disease. The pill has the potential to make a significant impact on overall health.
While CPACC is still undergoing trials, other companies, including Eli Lilly and Novo Nordisk, are also working on weight loss tablets. However, these alternatives have been associated with alarming side effects, such as sagging skin, gastrointestinal distress, and even suicidal ideation. Thus, there is a need for safer and more effective options in the weight loss market.
Overall, CPACC shows promising potential as a game-changing weight loss pill that could help individuals struggling with weight management. As clinical trials progress, further research will determine its safety and effectiveness, with the hope of providing a new solution for those looking to shed pounds without extreme dieting.